In a recent preclinical investigation, they were the first to show that TrkB agonist treatments (LM22A-4) remedied spatial memory impairment in AD mouse models, at least partly through mechanisms involved in positive influences on mitochondrial functioning and lowering of amyloid burden [146]. The gene discussed is NTRK2; the disease is Alzheimer disease.